Ling Zhen

Part of ClinChoice Medical (TIANJIN) Co., Ltd., Fountain Medical Development Ltd. is a clinical CRO that provides one-stop services for biomedical and medical equipment customers. Clinchoice has been accelerating drug and device approvals to market for more than 25 years and offers services such as project management, clinical operations, biological statistics, data management, registered affairs, medical affairs, and drug warning. The quality service runs through every link of the Clinchoice Kunyu service, and the quality assurance team is an independent team that focuses on the construction and continuous improvement of the American company's internal quality management system. The company was founded by Dan Zhang and Ling Zhen has been the CEO of the company since 2020. Laibiyi was founded in 2016 and is committed to solving the pain points of clinical research through in-depth cooperation with hospitals and a clinical research center that builds standardized standards. In 2021, Clinchoice Kunzhe acquired Laibiyi Technology (Xiamen) Co., Ltd. to further improve its phase I clinical trial platform.

Part of ClinChoice Medical (TIANJIN) Co., Ltd., Fountain Medical Development Ltd. is a clinical CRO that provides one-stop services for biomedical and medical equipment customers. Clinchoice has been accelerating drug and device approvals to market for more than 25 years and offers services such as project management, clinical operations, biological statistics, data management, registered affairs, medical affairs, and drug warning. The quality service runs through every link of the Clinchoice Kunyu service, and the quality assurance team is an independent team that focuses on the construction and continuous improvement of the American company's internal quality management system. The company was founded by Dan Zhang and Ling Zhen has been the CEO of the company since 2020. Laibiyi was founded in 2016 and is committed to solving the pain points of clinical research through in-depth cooperation with hospitals and a clinical research center that builds standardized standards. In 2021, Clinchoice Kunzhe acquired Laibiyi Technology (Xiamen) Co., Ltd. to further improve its phase I clinical trial platform.